Table 3.

Effects of sequential therapy on fungal burdens of mice infected with C. neoformans 2337a

Study no.Therapy (dose [mg/kg/day])Log10 CFU/g in the following tissues:
LungBrainKidneyLiverSpleen
MeanRangeMeanRangeMeanRangeMeanRangeMeanRange
3None10.28.7–10.57.56.9–7.97.36.1–7.67.46.8–7.67.37.0–7.5
FLC8.2b,c 7.1–8.76.6b 5.9–6.85.9b 5.2–6.26.2b 5.3–6.76.0b 5.3–6.4
AmB10.67.8–11.26.6b 5.7–7.15.4b 4.5–5.76.3b 5.7–6.76.5b 4.8–6.9
FLC-AmB6.7b,d,e 5.7–5.95.2b,d,e 3.7–5.74.7b,d 3.2–5.35.3b,e 3.2–5.74.2b,d,e 4.0–4.5
4None8.07.7–8.37.46.7–7.86.85.7–7.46.96.1–7.47.06.8–7.3
FLC7.77.0–8.07.36.6–7.76.65.8–7.16.85.9–7.26.95.7–7.2
AmB(0.5)4.8f 4.3–5.16.95.6–7.53.8f 3.3–4.33.6f 2.9–4.04.3f 3.2–4.9
AmB (1.5)3.0f,g 2.7–3.35.9f 5.0–6.42.7f,g 2.4–2.92.7f,g 0.3–3.43.3f,g 3.0–3.5
FLC-AmB (0.5)5.0f 4.1–5.37.13.6–7.44.0f 3.2–4.54.0f 2.6–4.54.6f 4.1–5.0
FLC-AmB (1.5)3.3f 1.4–3.82.9f,h 2.8–3.02.9f 2.6–3.12.5f 0.6–3.03.2f 3.0–3.4
  • a See the text for details. There were seven mice in each treatment group.

  • b P < 0.05 ,  any treatment versus control.

  • c P < 0.05 , FLC versus AmB.

  • d P < 0.05 , sequential therapy versus FLC.

  • e P < 0.05, sequential therapy versus AmB.

  • f P < 0.05 , any treatment versus control.

  • g P < 0.05 , AmB at 1.5 mg/kg/day versus AmB at 0.5 mg/kg/day.

  • h P < 0.05, sequential therapy versus AmB.